Friday, 21 August 2026 SourcesAbout🌓
🇮🇳 IN ▾
Américas🇧🇷 Brasil🇺🇸 United States🇨🇦 Canada🇻🇪 Venezuela🇲🇽 México🇦🇷 Argentina
Europa🇫🇷 France🇬🇧 United Kingdom🇪🇸 España🇵🇹 Portugal🇩🇪 Deutschland🇷🇺 Россия
Ásia-Pacífico🇯🇵 日本🇦🇺 Australia🇮🇳 India🇰🇷 대한민국🇨🇳 中国
África🇿🇦 South Africa
BREAKING
› Syrian Kurds announce completion of civil, military intergration with Damascus› Ex-SC judge Subhash Reddy to lead probe into action on CJP Parliament march› US Pushes Allies, China To Support Trump's Economic War On Iran› Somalia faces another hunger crisis and the UN food agency head says it has far less funds to help› The Vanashakti verdict is balanced and pragmatic› Canadian premier says Trump is a ‘bad person’ as Canada weighs concessions for trade deal› Salman Khan, Nayanthara film titled Monster: Report› Tasmania spent 28 years removing invasive carp from two lakes; after 49,301 fish were...› SCOOP: Alia Bhatt to make an extended appearance in Ranbir Kapoor and Deepika Padukone's Brahmastra 2› Tornado threat today: Which states and cities are under watch? See full list as Maryland, DC under alert› Syrian Kurds announce completion of civil, military intergration with Damascus› Ex-SC judge Subhash Reddy to lead probe into action on CJP Parliament march› US Pushes Allies, China To Support Trump's Economic War On Iran› Somalia faces another hunger crisis and the UN food agency head says it has far less funds to help› The Vanashakti verdict is balanced and pragmatic› Canadian premier says Trump is a ‘bad person’ as Canada weighs concessions for trade deal› Salman Khan, Nayanthara film titled Monster: Report› Tasmania spent 28 years removing invasive carp from two lakes; after 49,301 fish were...› SCOOP: Alia Bhatt to make an extended appearance in Ranbir Kapoor and Deepika Padukone's Brahmastra 2› Tornado threat today: Which states and cities are under watch? See full list as Maryland, DC under alert
Business

India's pharma ambitions are running into a regulatory capacity constraint

Business Standard ·
India's pharma ambitions are running into a regulatory capacity constraint

Govt's decision under the ₹10,000 cr Biopharma SHAKTI programme to create a dedicated scientific review cadre within CDSCO is an important reform

Read the full article on Business Standard ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.

More from Business Standard

See all ›

Kolkata's tryst with reforms: IT, retail gained but past glory elusive

Business Standard · 42 min ago

Need a human touch: Govt tells Meta not to leave takedowns solely to AI

Business Standard · 1 h ago

Green signal for blue water fishing: The permit could be a game changer

Business Standard · 1 h ago

AI lifts demand for flexible office spaces as firms seek workplace agility

Business Standard · 2 h ago

More in Business

See all ›

Kolkata's tryst with reforms: IT, retail gained but past glory elusive

Business Standard · 42 min ago

Need a human touch: Govt tells Meta not to leave takedowns solely to AI

Business Standard · 1 h ago

Green signal for blue water fishing: The permit could be a game changer

Business Standard · 1 h ago

AI lifts demand for flexible office spaces as firms seek workplace agility

Business Standard · 2 h ago

Cashfree Payments net loss at ₹118.5 cr in FY26; revenue jumps 51%

Business Standard · 2 h ago

India and Singapore ink pacts to strengthen ties in key sectors

Business Standard · 2 h ago